口服抗凝药对髋部骨折手术延迟与死亡率的影响
该系统综述与荟萃分析纳入34项研究共39,446例患者,比较院前使用口服抗凝药(OAC)与未使用者的手术时机和死亡率。结果显示OAC组手术时间延长13.7小时,超过48小时手术的比值比为3.0,院内死亡率比值比为1.4。直接口服抗凝药(DOAC)与维生素K拮抗剂(VKA)之间手术时间无显著差异。
要点
- 髋部骨折患者院前使用OAC与手术时间延长13.7小时相关。
- OAC组超过推荐48小时手术的比值比为3.0(95%CI 2.1-4.3)。
- OAC组院内死亡率比值比为1.4(95%CI 1.0-1.8)。
核心结论
- 院前使用OAC的髋部骨折患者手术时间延迟且死亡率高于未抗凝患者。
- 使用DOAC的患者可能面临进一步的手术延迟风险。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、EMBASE和Cochrane Central Register of Controlled Trials自建库至2019年10月14日。
- 纳入34项研究,涉及39,446例患者,比较院前使用DOAC或VKA的髋部骨折患者与未使用OAC患者。
- 采用随机效应荟萃分析合并手术时间、院内死亡率和30天死亡率等结局。
主要发现
- OAC组手术时间较非OAC组延长13.7小时(95%CI 9.8-17.5;p<0.001)。
- OAC组超过入院后推荐48小时手术的比值比为3.0(95%CI 2.1-4.3;p=0.001)。
- OAC组院内死亡率比值比为1.4(95%CI 1.0-1.8;p<0.03)。
- 比较DOAC与VKA的研究中,手术时间无统计学显著差异。
关键数值与推荐
- 当前指南推荐髋部骨折患者在就诊后48小时内手术。
- OAC组手术时间延长13.7小时(95%CI 9.8-17.5;p<0.001)。
- 超过48小时手术的OR为3.0(95%CI 2.1-4.3;p=0.001)。
- 院内死亡率OR为1.4(95%CI 1.0-1.8;p<0.03)。
临床怎么用
- 对院前使用OAC的髋部骨折患者应评估加速手术方案以减少延迟。
- 使用DOAC的患者可能需要特别关注手术时机。
局限性
- 原始研究样本量小且结局异质性大。
- 未报告30天死亡率的具体合并结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Current guidelines recommend surgery within 48 hours among patients presenting with hip fractures; however, optimal surgical timing for patients on oral anticoagulants (OACs) remains unclear. Individual studies are limited by small sample sizes and heterogeneous outcomes. The aim of this study was to conduct a systematic review and meta-analysis to summarize the effect of pre-injury OACs on time-to-surgery (TTS) and all-cause mortality among older adults with hip fracture treated surgically. METHODS: We searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception to 14 October 2019 to identify studies directly comparing outcomes among hip fracture patients receiving direct oral anticoagulants (DOACs) or vitamin K antagonists (VKAs) prior to hospital admission to hip fracture patients not on OACs. Random effects meta-analyses were used to pool all outcomes (TTS, in-hospital mortality, and 30-day mortality). RESULTS: A total of 34 studies (involving 39,446 patients) were included in our systematic review. TTS was 13.7 hours longer (95% confidence interval (CI) 9.8 to 17.5; p < 0.001) among hip fracture patients on OACs compared to those not on OACs. This translated to a three-fold higher odds of having surgery beyond the recommended 48 hours from admission (odds ratio (OR) 3.0 (95% CI 2.1 to 4.3); p = 0.001). In-hospital mortality was higher (OR 1.4 (95% CI 1.0 to 1.8); p < 0.03) among anticoagulated patients. Among studies comparing anticoagulants, there was no statistically significant difference in time-to-surgery between patients taking a DOAC compared to a VKA. CONCLUSION: Patients presenting with a hip fracture who were taking OACs prior to injury experience a delay in time-to-surgery and higher mortality than non-anticoagulated patients. Patients on DOACs may be at risk of further delays. Evaluating expedited surgical protocols in hip fracture patients on OACs is an urgent priority, with the potential to decrease morbidity and mortality in this group of high-risk patients. Cite this article: Bone Joint J 2021;103-B(2):222-233.
引用
- You D, Xu Y, Ponich B, et al. Effect of oral anticoagulant use on surgical delay and mortality in hip fracture. Bone Joint J. 2021. PMID: 33517730. doi:10.1302/0301-620X.103B2.BJJ-2020-0583.R2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。